Investigations on oxidative stress and therapeutical implications in dementia
- PMID: 10654103
- DOI: 10.1007/pl00014177
Investigations on oxidative stress and therapeutical implications in dementia
Abstract
Alzheimer's disease (AD) is a progressive dementia affecting a large proportion of the aging population. The histopathological changes in AD include neuronal cell death and formation of amyloid plaques and neurofibrillary tangles (NFTs) NFTs are composed of hyperphosphorylated tau protein, and senile plaques contain aggregates of the beta-peptide. There is also evidence that brain tissue in patients with AD is exposed to oxidative stress during the course of the disease. Advanced glycation endproducts (AGEs), which are formed by a non-enzymatic reaction of glucose with long-lived protein deposits, are potentially toxic to the cell, are present in brain plaques in AD, and its extracellular accumulation in AD may be caused by an accelerated oxidation of glycated proteins. The microtubuli-associated protein tau is also subject to intracellular AGE formation. AGEs participate in neuronal death causing direct (chemical) radical production: Glycated proteins produce nearly 50-fold more radicals than non-glycated proteins, and indirect (cellular) radical production: Interaction of AGEs with cells increases oxidative stress. During aging cellular defence mechanisms weaken and the damages to cell constituents accumulate leading to loss of function and finally cell death. The development of drugs for the treatment of AD remains at a very unsatisfying state. However, pharmacological approaches which break the vicious cycles of oxidative stress and neurodegeneration offer new opportunities for the treatment of AD. Theses approaches include AGE-inhibitors, antioxidants, and anti-inflammatory substances, which prevent radical production. AGE inhibitors might be able to stop formation of AGE-modified beta-amyloid deposits, antioxidants are likely to scavenge intracellular and extracellular superoxide radicals and hydrogen peroxide before these radicals damage cell constituents or activate microglia, and anti-inflammatory drugs attenuating microglial radical and cytokine production.
Similar articles
-
Oxidative stress in Alzheimer disease.Cell Adh Migr. 2009 Jan-Mar;3(1):88-93. doi: 10.4161/cam.3.1.7402. Epub 2009 Jan 13. Cell Adh Migr. 2009. PMID: 19372765 Free PMC article. Review.
-
[Alzheimer disease: cellular and molecular aspects].Bull Mem Acad R Med Belg. 2005;160(10-12):445-9; discussion 450-1. Bull Mem Acad R Med Belg. 2005. PMID: 16768248 French.
-
Histochemical accumulation of oxidative damage products is associated with Alzheimer-like pathology in the canine.Amyloid. 2004 Jun;11(2):90-100. doi: 10.1080/13506120412331285779. Amyloid. 2004. PMID: 15478464
-
Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.JAMA Neurol. 2014 Apr;71(4):505-8. doi: 10.1001/jamaneurol.2013.5847. JAMA Neurol. 2014. PMID: 24493463 Review.
-
Oxidative stress hypothesis in Alzheimer's disease.Free Radic Biol Med. 1997;23(1):134-47. doi: 10.1016/s0891-5849(96)00629-6. Free Radic Biol Med. 1997. PMID: 9165306 Review.
Cited by
-
Glycation Damage: A Possible Hub for Major Pathophysiological Disorders and Aging.Aging Dis. 2018 Oct 1;9(5):880-900. doi: 10.14336/AD.2017.1121. eCollection 2018 Oct. Aging Dis. 2018. PMID: 30271665 Free PMC article. Review.
-
Flavan-3-ol compounds from wine wastes with in vitro and in vivo antioxidant activity.Nutrients. 2010 Oct;2(10):1048-59. doi: 10.3390/nu2101048. Epub 2010 Oct 11. Nutrients. 2010. PMID: 22253995 Free PMC article.
-
Targeting Inflammatory Pathways in Alzheimer's Disease: A Focus on Natural Products and Phytomedicines.CNS Drugs. 2019 May;33(5):457-480. doi: 10.1007/s40263-019-00619-1. CNS Drugs. 2019. PMID: 30900203 Review.
-
Protective role of S-nitrosoglutathione (GSNO) against cognitive impairment in rat model of chronic cerebral hypoperfusion.J Alzheimers Dis. 2013;34(3):621-35. doi: 10.3233/JAD-121786. J Alzheimers Dis. 2013. PMID: 23254638 Free PMC article.
-
Central nervous system involvement in the animal model of myodystrophy.Mol Neurobiol. 2013 Aug;48(1):71-7. doi: 10.1007/s12035-013-8415-9. Epub 2013 Mar 19. Mol Neurobiol. 2013. PMID: 23508358
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical